Acromegaly Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 7.40 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Acromegaly Treatment Market Analysis
The Acromegaly Treatment Market is expected to register a CAGR of 7.4% during the forecast period, 2022-2027.
The COVID-19 pandemic has significantly impacted acromegaly treatment. For instance, as per a November 2020 published article titled, "Growth hormone deficiency, acromegaly, and COVID-19: Transitioning from media reports to knowledge and a growth hormone hypothesis", having acromegaly does theoretically increase the risk of COVID-19 because of its associated comorbidities such as cardiovascular complications, diabetes mellitus, obstructive sleep apnea syndrome, chest wall deformity, upper airway obstruction, and intrathoracic collapse. Additionally, per a March 2021 published article titled, "Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting", patients with acromegaly have several characteristics that could potentially worsen their outcome if they develop COVID-19. Thus, such studies indicate that patients with COVID-19 disease are at high risk. Hence, the demand for acromegaly treatment is expected to increase in the near future.
Further, the significant factors contributing to the market's growth are the increasing prevalence and incidence of acromegaly and pituitary tumors; growing awareness regarding the disease worldwide; and technological advancements in developing new drugs for acromegaly.
The increasing prevalence of acromegaly and pituitary tumors is boosting the market growth. For instance, as per a May 2021 published article, "Descriptive Epidemiology and Survival Analysis of Acromegaly in Korea," the average annual incidence was 4.2 per million per year, and the prevalence was 32.1 cases per million during this period. Also, as per a July 2021 published article titled, "Global epidemiology of acromegaly: a systematic review and meta-analysis," the results revealed that out of a total of 32 studies included in the systematic review and 22 of them included in the meta-analysis, the pooled prevalence of acromegaly was 5.9 per 100,000 people. Moreover, as per a 2020 update by the Australian Pituitary Foundation, between 715 and 3,500 Australians currently live with acromegaly, representing around one person with acromegaly every 7,300 to 35,700 Australians. Thus, the statistics indicate that the demand for acromegaly treatment will increase shortly, thereby contributing to market growth.
However, complications associated with the treatment are a significant factor restraining the market's growth.
Acromegaly Treatment Market Trends
This section covers the major market trends shaping the Acromegaly Treatment Market according to our research experts:
Somatostatin Analogs Segment is Expected to Hold a Major Market Share in the Acromegaly Treatment Market
The somatostatin analogs segment is anticipated to hold a significant market share by product type. This can be attributed to the wide availability of drugs and cost-efficiency. Somatostatin analogs have been prescribed as first-line treatment options as they are highly effective. Some examples of available marketed drugs are somavert, Signifor LAR, Sandostatin LAR, Somatuline Depot, and Parlodel.
Also, the increasing number of product approvals is driving the market's growth. For instance, in June 2020, Chiasma, Inc., a commercial-stage biopharmaceutical company, reported that the United States Food and Drug Administration (FDA) approved MYCAPSSA(octreotide) capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first, and only oral somatostatin analog (SSA) approved by the FDA and the first product approved by the FDA utilizing Chiasma's Transient Permeability Enhancer (TPE) technology. Also, in June 2021, the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly.
Thus, the market is expected to witness significant growth over the forecast period due to the abovementioned factors.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global acromegaly treatment market due to the high demand for innovative products. According to the National Institutes of Health (NIH) and Endocrine Society, in 13 studies of acromegaly prevalence, researchers estimate that roughly 24,000 individuals live with acromegaly in the United States, of which an estimated 8,000 people are treated chronically with somatostatin analog injections.
Furthermore, the presence of top pharma and biotech companies involved in developing products for acromegaly treatment is contributing to the market's growth. For instance, in June 2021, Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported the randomization of the first acromegaly patient in its Phase 3 clinical trial of paltusotine, PATHFNDR-1. This trial will be one of two planned Phase 3 studies assessing the safety and efficacy of once-daily oral paltusotine in acromegaly patients that together will evaluate paltusotine in a broad cross-section of acromegaly patients.
Thus, the market is expected to witness significant growth over the forecast period due to the above developments.
Acromegaly Treatment Industry Overview
The Acromegaly treatment market is consolidated and competitive and consists of a few significant players. Some prominent players operating in the acromegaly market are Pfizer Inc., Novartis AG, Validus Pharmaceuticals LLC, and Ipsen. Some companies involved in developing products for acromegaly are Chiasma, Inc., Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Inc., and Midatech Pharma Plc.
Acromegaly Treatment Market Leaders
-
Pfizer Inc
-
Ipsen
-
Chiasma, Inc
-
Validus Pharmaceuticals LLC
-
Novartis AG
*Disclaimer: Major Players sorted in no particular order
Acromegaly Treatment Market News
- In November 2021, ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, launched MYRELEZ (lanreotide) in Norway, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumors and symptoms associated with neuroendocrine tumors.
- In September 2021, Amolyt Pharma and PeptiDream Inc. reported that Amolyt Pharma had exercised its option to globally license a portfolio of macrocyclic peptide growth hormone receptor antagonists (GHRA) under the terms of its research collaboration agreement to develop AZP-3813 as a potential treatment for acromegaly following successful research collaboration between the two companies. The identified, optimized drug candidate, AZP-3813, is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogs (SSAs) for patients who do not adequately respond to SSAs alone.
Acromegaly Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence and Incidence of Acromegaly and Pituitary Tumors
- 4.2.2 Growing Awareness Regarding Acromegaly Disease Worldwide
- 4.2.3 Technological Advancements in Development of New Drugs for Acromegaly
-
4.3 Market Restraints
- 4.3.1 Complications Associated with the Treatment
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Product Type
- 5.1.1 Somatostatin Analogs
- 5.1.2 Growth Hormone Receptor Antagonist (GHRA)
- 5.1.3 Dopamine Agonists
- 5.1.4 Other Product Types
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Mexico
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 United Kingdom
- 5.2.2.3 France
- 5.2.2.4 Italy
- 5.2.2.5 Spain
- 5.2.2.6 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Middle-East and Africa
- 5.2.4.1 GCC
- 5.2.4.2 South Africa
- 5.2.4.3 Rest of Middle-East and Africa
- 5.2.5 South America
- 5.2.5.1 Brazil
- 5.2.5.2 Argentina
- 5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc
- 6.1.2 Novartis AG
- 6.1.3 Validus Pharmaceuticals LLC
- 6.1.4 Ipsen
- 6.1.5 Chiasma, Inc
- 6.1.6 Crinetics Pharmaceuticals
- 6.1.7 Ionis Pharmaceuticals Inc
- 6.1.8 Midatech Pharma Plc
- 6.1.9 ADVANZ PHARMA
- 6.1.10 Amolyt Pharma
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAcromegaly Treatment Industry Segmentation
As per the scope of the report, acromegaly is a rare acquired endocrine disease related to excessive growth hormone production and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations. The market is segmented By Product Type (Somatostatin Analogs, Growth Hormone Receptor Antagonist (GHRA), Dopamine Agonists, Other Product Types), and Geography(North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Product Type | Somatostatin Analogs | |
| Growth Hormone Receptor Antagonist (GHRA) | ||
| Dopamine Agonists | ||
| Other Product Types | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Acromegaly Treatment Market Research FAQs
What is the current Global Acromegaly Treatment Market size?
The Global Acromegaly Treatment Market is projected to register a CAGR of 7.40% during the forecast period (2024-2029)
Who are the key players in Global Acromegaly Treatment Market?
Pfizer Inc, Ipsen, Chiasma, Inc, Validus Pharmaceuticals LLC and Novartis AG are the major companies operating in the Global Acromegaly Treatment Market.
Which is the fastest growing region in Global Acromegaly Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Acromegaly Treatment Market?
In 2024, the North America accounts for the largest market share in Global Acromegaly Treatment Market.
What years does this Global Acromegaly Treatment Market cover?
The report covers the Global Acromegaly Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Acromegaly Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Acromegaly Treatment Industry Report
Statistics for the 2023 Acromegaly Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Acromegaly Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
